Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook
Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.